IP Library › Granted Patent US 12,252,494
Granted Patent B2
US 12,252,494 · App. 18/077,431 · Granted Mar 18, 2025

Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis

Inventors: Brenton Mar (Cambridge, MA); Anthony L. Boral (Cambridge, MA); Hui-Min Lin (Cambridge, MA); Hongliang Shi (Cambridge, MA)
Assignee: Blueprint Medicines Corporation
C07D487/04A61P17/00A61P35/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,494
App. No.
18/077,431
Granted
Mar 18, 2025
Kind
B2
Abstract

Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.

Claims (9)

1. A method of treating a patient with indolent systemic mastocytosis (ISM) comprising administering to the patient 25 mg of Compound (I) once daily:

or administering to the patient a pharmaceutically acceptable salt of Compound (I) in an amount equivalent to 25 mg of Compound (I) once daily.

2. The method of claim 1 , wherein the patient has a mutation in Exon 17 in KIT.

3. The method of claim 2 , wherein the patient has a D816 mutation in KIT in Exon 17.

4. The method of claim 3 , wherein the D816 mutation is D816V.

5. The method of claim 1 , wherein the patient has a minimum total symptom score (TSS) of >28 as assessed using the indolent systemic mastocytosis-symptom assessment form (ISM-SAF).

6. The method of claim 1 , further comprising administering an effective amount of an antihistamine.

7. The method of claim 1 , wherein 25 mg of Compound (I):

is administered to the patient once daily.

Assignments (4)
RELEASE OF SECURITY INTEREST (REEL/FRAME 064748/0552) Recorded Jul 24, 2025
From: TAO TALENTS, LLC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 072249/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2024
From: BORAL, ANTHONY L.; LIN, HUI-MIN; SHI, HONGLIANG
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 069599/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2024
From: MAR, BRENTON
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 066149/0234 →
SECURITY INTEREST Recorded Aug 29, 2023
From: BLUEPRINT MEDICINES CORPORATION
To: TAO TALENTS, LLC
Reel/Frame 064748/0552 →
Continuity (6)
Continuation 17153727 · Jan 20, 2021
Continuation PCTUS2020027724 · Apr 10, 2020
Provisional Application 62990269 · Mar 16, 2020
Provisional Application 62844575 · May 7, 2019
Provisional Application 62833527 · Apr 12, 2019
Related Publication 20230124801A1 · Apr 20, 2023
References Cited (160)
US 6982265B1 · Hunt et al. · 2006 [cited by applicant]
US 7244733B2 · Hunt et al. · 2007 [cited by applicant]
US 8609672B2 · Russu et al. · 2013 [cited by applicant]
US 8802697B2 · Bifulco, Jr. et al. · 2014 [cited by applicant]
US 9126951B2 · Bifulco, Jr. et al. · 2015 [cited by applicant]
US 9200002B2 · Hodous · 2015 [cited by examiner]
US 9334263B2 · Hodous et al. · 2016 [cited by applicant]
US 9340514B2 · Bifulco, Jr. et al. · 2016 [cited by applicant]
US 9434700B2 · Bifulco, Jr. et al. · 2016 [cited by applicant]
US 9499522B2 · DiPietro et al. · 2016 [cited by applicant]
US 9688680B2 · Hodous · 2017 [cited by applicant]
US 9695165B2 · Bifulco, Jr. et al. · 2017 [cited by applicant]
US 9884861B2 · Hodous et al. · 2018 [cited by applicant]
US 9944651B2 · Hodous et al. · 2018 [cited by applicant]
US 9994552B2 · DiPietro et al. · 2018 [cited by applicant]
US 9994575B2 · Hodous et al. · 2018 [cited by applicant]
US 10000490B2 · Bifulco, Jr. et al. · 2018 [cited by applicant]
US 10000496B2 · Hodous et al. · 2018 [cited by applicant]
US 10017512B2 · Wenglowsky et al. · 2018 [cited by applicant]
US 10030005B2 · Brubaker et al. · 2018 [cited by applicant]
US 10035789B2 · Brubaker et al. · 2018 [cited by applicant]
US 10202365B2 · Brooijmans et al. · 2019 [cited by applicant]
US 10227329B2 · Brubaker et al. · 2019 [cited by applicant]
US 10584114B2 · Brubaker et al. · 2020 [cited by applicant]
US 10807985B2 · Hodous et al. · 2020 [cited by applicant]
US 11046697B2 · Wenglowsky et al. · 2021 [cited by applicant]
US 11999744B2 · Waetzig et al. · 2024 [cited by applicant]
US 20040186140A1 · Cherney et al. · 2004 [cited by applicant]
US 20060211695A1 · Borzilleri et al. · 2006 [cited by applicant]
US 20140187559A1 · Miduturu · 2014 [cited by applicant]
US 20160031892A1 · Hodous · 2016 [cited by applicant]
US 20160102097A1 · Hodous et al. · 2016 [cited by applicant]
US 20170022206A1 · Hodous et al. · 2017 [cited by applicant]
US 20170029409A1 · DiPietro et al. · 2017 [cited by applicant]
US 20170066773A1 · Wenglowsky et al. · 2017 [cited by applicant]
US 20170066812A1 · Bifulco, Jr. et al. · 2017 [cited by applicant]
US 20170119760A1 · Moussy et al. · 2017 [cited by applicant]
US 20170121312A1 · Brubaker et al. · 2017 [cited by applicant]
US 20170145018A1 · Wenglowsky et al. · 2017 [cited by applicant]
US 20170174652A1 · Bifulco, Jr. et al. · 2017 [cited by applicant]
US 20170204104A1 · Hodous et al. · 2017 [cited by applicant]
US 20170253593A1 · Bifulco, Jr. et al. · 2017 [cited by applicant]
US 20170267661A1 · Kim et al. · 2017 [cited by applicant]
US 20170298069A1 · Brooijmans et al. · 2017 [cited by applicant]
US 20180022731A1 · Brooijmans et al. · 2018 [cited by applicant]
US 20180022732A1 · Brubaker et al. · 2018 [cited by applicant]
US 20180362613A1 · Bifulco, Jr. et al. · 2018 [cited by applicant]
US 20190119280A1 · Hodous et al. · 2019 [cited by applicant]
US 20200024280A1 · Hodous et al. · 2020 [cited by applicant]
US 20210147433A1 · Waetzig et al. · 2021 [cited by applicant]
US 20220370465A1 · Mar · 2022 [cited by examiner]
US 20230271971A1 · Waetzig et al. · 2023 [cited by applicant]
CN 102040494A · 2011 [cited by applicant]
CN 108191874A · 2018 [cited by applicant]
CN 110938077A · 2020 [cited by applicant]
CN 110950872A · 2020 [cited by applicant]
EP 0200968A1 · 1986 [cited by applicant]
JP 2003519698A · 2003 [cited by applicant]
JP 2005503372A · 2005 [cited by applicant]
JP 2006519205A · 2006 [cited by applicant]
JP 2007535558A · 2007 [cited by applicant]
JP 2008504366A · 2008 [cited by applicant]
JP 2009514882A · 2009 [cited by applicant]
JP 2009542814A · 2009 [cited by applicant]
JP 6446040B2 · 2018 [cited by applicant]
JP 2019522051A · 2019 [cited by applicant]
RU 2331640C2 · 2008 [cited by applicant]
WO WO2000071129A1 · 2000 [cited by applicant]
WO WO2001025220A1 · 2001 [cited by applicant]
WO 200174821A1 · 2001 [cited by applicant]
WO WO2003010158A1 · 2003 [cited by applicant]
WO WO2003090912A1 · 2003 [cited by applicant]
WO WO2004071460A2 · 2004 [cited by applicant]
WO WO2004076450A1 · 2004 [cited by applicant]
WO WO2005117909A2 · 2005 [cited by applicant]
WO WO2006004636A2 · 2006 [cited by applicant]
WO WO2006028524A2 · 2006 [cited by applicant]
WO WO2007056170A2 · 2007 [cited by applicant]
WO WO2007065100A1 · 2007 [cited by applicant]
WO WO2007085188A1 · 2007 [cited by applicant]
WO WO2008005956A2 · 2008 [cited by applicant]
WO WO2009015254A1 · 2009 [cited by applicant]
WO WO2009117157A1 · 2009 [cited by applicant]
WO WO2010002095A2 · 2010 [cited by applicant]
WO WO2010022055A2 · 2010 [cited by applicant]
WO WO2010144345A1 · 2010 [cited by applicant]
WO WO2011005119A1 · 2011 [cited by applicant]
WO WO2011103196A1 · 2011 [cited by applicant]
WO WO2012027495A1 · 2012 [cited by applicant]
WO WO2014039714A2 · 2014 [cited by applicant]
WO WO2014100620A2 · 2014 [cited by applicant]
WO WO2014160521A1 · 2014 [cited by applicant]
WO WO2015057873A1 · 2015 [cited by applicant]
WO WO2015058129A1 · 2015 [cited by applicant]
WO WO2016022569A1 · 2016 [cited by applicant]
WO WO2017019442A1 · 2017 [cited by applicant]
WO WO2018049233A1 · 2018 [cited by applicant]
WO WO2018183712A1 · 2018 [cited by applicant]
WO WO2019034128A1 · 2019 [cited by applicant]
WO 2019152719A1 · 2019 [cited by applicant]
WO WO2020102095A1 · 2020 [cited by applicant]
WO WO2020210669A1 · 2020 [cited by applicant]
WO WO2021004895A1 · 2021 [cited by applicant]
WO WO2021079134A1 · 2021 [cited by applicant]
A precision therapy against cancers driven by KIT/PDGFRA mutations Evans et al. Science Translational Medicine, Nov. 1, 2017, vol. 9, Issue 414 DOI: 10.1126/scitranslmed.aao 1690 (Year: 2017). [cited by examiner]
Kit D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis Broesby-Olsen et al. J Allergy Clin Immunol, Sep. 2013 https://doi.org/10.1016/j.jaci.2013.02.019 (Year: 2013). [cited by examiner]
Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1 Study Deininger et al. www.blueprintmedicines.… [cited by examiner]
Akin et al., Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therap… [cited by applicant]
Akin, Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. 61st… [cited by applicant]
Antonescu, What lessons can be learned from the GIST paradigm that can be applied to other kinase-driven cancers. J Pathol. Jan. 2011;223(2):251-261. [cited by applicant]
Bennett et al., Cecil Textbook of Medicine, 20th Edition, vol. 1, W.B. Saunders Company, Philadelphia. pp. 1004-1010, (1996). [cited by applicant]
Blueprint Medicines, 2020 Blueprint global business strategy. 32 pages, Jan. 7, 2019. [cited by applicant]
Blueprint Medicines, Blueprint Medicines Announces Part 1 Results from Pioneer Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic … [cited by applicant]
Blueprint Medicines, Precision That Moves™ Staying one step ahead of disease. J.P. Morgan Healthcare Conference, 35 pages, Jan. 13-16, 2020. [cited by applicant]
Cairo, Crystalline Polymorphism of Organic Compounds. Topics in Current Chemistry. Design of Organic Solids. Springer. E. Weber (Ed.). vol. 198, pp. 163-208, Jan. 1998. [cited by applicant]
Cairoli et al., Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. May 1, 2006;107(9):3463-8. [cited by applicant]
Cohen, The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol. Aug. 1999;3(4):459-65. [cited by applicant]
Dermer, Another Anniversary for the War on Cancer. Bio/Technology. Mar. 1994;12:320. [cited by applicant]
Drummond et al., Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM). American Society of Hematology Annual Meeting. 19… [cited by applicant]
Freshney, Culture of Animal Cells, a Manual of Basic Technique. Alan R. Liss, Inc. pp. 1-6, (1983). [cited by applicant]
Gotlib et al., Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM). American Society of Hematology Annual Meeting. 18 pages, Dec. 2, 2018. [cited by applicant]
Heinrich et al., Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRalpha activation loop mutants in advanced gastrointestinal stromal tumo… [cited by applicant]
Hilfiker et al., Relevance of Solid-state Properties for Pharmaceutical Products. Polymorphism: in the Pharmaceutical Industry. Wiley-VCH Verlag Gmbh & Co. Chapter 1, pp. 1-19. Feb. 6, 2006. [cited by applicant]
InvivoChem—Material Safety Data Sheet (MSDS). Retrieved online at: https://www.invivochem.com/avapritinib.html. 6 pages, Apr. 21, 2017. [cited by applicant]
Lee et al., Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. J Gastrointestin Liver Dis. Dec. 2013;22(4):413-8. [cited by applicant]
Paschka et al., Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. Aug. 20, 2006;24(24):3904-11. [cited by applicant]
Quintela et al., A Ready One-pot Preparation for Pyrrolo[2,1-f]-[1,2,4]triazine and Pyrazolo[5,1-c]pyrimido[4,5-e]-[1,2,4]triazine Derivatives. Tetrahedron. 1996;52(8):3037-3048. [cited by applicant]
Schnittger et al., KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799. [cited by applicant]
Selleckchem, Safety Data Sheet. Retrieved online at: https://www.selleckchem.com/products/blu-285.html. 6 pages, Jan. 16, 2019. [cited by applicant]
Shallal et al., Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. Eur J Med Chem. Jun. 2011;46(6):2043-57. [cited by applicant]
Wu et al., Avapritinib: A Selective Inhibitor of KIT and PDGFR? that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. Jul. 1, 2019;16(7):3040-3052. [cited by applicant]
Indian Office Action for Application No. 201617009956, dated Nov. 26, 2019, 7 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2014/027008, dated Jul. 24, 2014, 11 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2014/060746, dated Dec. 17, 2014, 8 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2014/061211, dated Dec. 10, 2014, 9 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2015/043624, dated Oct. 6, 2015, 7 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2016/043301, dated Oct. 17, 2016, 10 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2018/025193, dated May 30, 2018, 10 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/027724, dated Sep. 23, 2020, 18 pages. [cited by applicant]
Japanese Office Action for Application No. 2018-224481, dated Mar. 30, 2020, 7 pages. [cited by applicant]
Zhang et al., Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. Apr. 2, 2013;110(14):5689-94. [cited by applicant]
Bavin, Polymorphism in Process Development. Chemistry & Industry. Aug. 1989;21:527-529. [cited by applicant]
Brittain, Polymorphism in Pharmaceutical Salts, Second Edition. informa healthcare, New York. pp. 333-338, (2009). [cited by applicant]
Buttner et al., Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol. Dec. 1998;111(6):1227-… [cited by applicant]
Byrn et al., Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res. Jul. 1995;12(7):945-54. [cited by applicant]
European Pharmacopoeia, Characterisation of Crystalline and Partially Crystalline Solids by X-Ray Powder Diffraction (XRPD). 2.9.33. pp. 301-305, (2011). [cited by applicant]
Grunenberg, Polymorphie und Thermische Analyse, pharmazeutischer Wirkstoffe. Pharmazie in unserer Zeit;1997;5:224-231. [cited by applicant]
Guillory, Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids. Drugs and the Pharmaceutical Sciences. 1999;95:183-226. [cited by applicant]
Kawaguchi et al., Drug and crystal polymorphism. Journal of Human Environmental Engineering. 2002;4(2):310-317. [cited by applicant]
Lippold et al., Lehrbuch der Pharmazeutischen Technologie. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. pp. 214-217, (2006). [cited by applicant]
Mitsuhisa, Approach to Crystal Polymorph in Process Research of New Drugs. Journal of the Society for Synthetic Organic Chemistry. 2007;65(9):907-913. [cited by applicant]
Oppelt et al., Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. Jun. 2017;8(3):466-473. [cited by applicant]
Pharmaceutical Affairs Bureau No. 568, Establishment of Specifications and Test Methods for New Drugs. 106 pages, May 1, 2001. [cited by applicant]
Declaration of Technical Expert. 6 pages, Nov. 16, 2021. [cited by applicant]
U.S. Appl. No. 17/153,727, filed Jan. 20, 2021, 2021-0147433, Published. [cited by applicant]
U.S. Appl. No. 18/077,466, filed Dec. 8, 2022, 2023-0271971, Allowed. [cited by applicant]
U.S. Appl. No. 18/543,793, filed Dec. 18, 2023, Pending. [cited by applicant]
Lubke et al., Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Leukemia. May 2019;33(5):1195-1205. [cited by applicant]
Pardanani, Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. Mar. 2019;94(3):363-377. [cited by applicant]
Vaes et al., Targeted Treatment Options in Mastocytosis. Front Med (Lausanne). Jul. 20, 2017;4:110, 12 pages. [cited by applicant]